Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

University of California San Francisco (UCSF)

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Glatiramer acetate

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00819195

10-03877

Details and patient eligibility

About

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

Enrollment: 17 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Relapsing-remitting (RR) MS patients (McDonald criteria)
• Ages 18-55
• Males and females
• EDSS score ≤5
• No prior treatment with Copaxone
• Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month

Exclusion criteria

• Treatment with Tysabri, Novantrone or cyclophosphamide
• Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate)
• Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis
• Pregnancy

Trial design

17 participants in 2 patient groups

RRMS

Description:

Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care

Treatment:

Drug: Glatiramer acetate

HC

Description:

Healthy control volunteers